Pharmaceuticals
Mayne Pharma Launches Chlorzoxazone Tablet in the United States
ADELAIDE, Australia, July 27, 2020 /PRNewswire/ -- Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that the US Food and Drug Administration (FDA) has granted approval of its Abbreviated New Drug Application (ANDA) for chlorzoxazone tablet, 375 mg, 500 mg and 750 mg, inthe United Stat...
2020-07-28 12:02
7910
Sherpa Healthcare Partners Announces Close of Oversubscribed Fund
BEIJING, July 27, 2020 /PRNewswire/ -- Sherpa Healthcare Partners is pleased to announce the final closing of the oversubscribed Sherpa Healthcare Fund I, L.P. The fund focuses on early- to growth-stage investment in the healthcare sector to cover companies in biotech, biopharma, medical devices ...
2020-07-28 11:33
2480
Clarity Pharmaceuticals opens SARTATE neuroblastoma clinical trial
SYDNEY, July 23, 2020 /PRNewswire/ -- Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has opened its trial of67Cu-SARTATE™ for paediatric patients with neuroblastoma at Memorial Sloan Kettering Cancer Center (MSK) ...
2020-07-23 21:13
2038
GenScript launches CDMO segment "GenScript ProBio" at inaugural GenScript Cell and Gene Therapy Industry Development & Cooperation Forum
SHANGHAI, July 21, 2020 /PRNewswire/ -- The inaugural GenScript Cell and Gene Therapy Industry Development & Cooperation Forum successfully concluded in Shanghai on July 17, at which more than 700 authoritative researchers and corporate leaders shared insights on the future growth of the cell and ...
2020-07-21 22:04
2725
Clarity Pharmaceuticals and ImaginAb to Collaborate on New Cancer Targets
SYDNEY and LOS ANGELES, July 21, 2020 /PRNewswire/ -- Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, and ImaginAb, Inc., a company that harnesses the specificity of monoclonal antibodies, have entered into a collaboration agreement to develop n...
2020-07-21 21:13
2095
Samsung Biologics Expands Drug Product Manufacturing Facility in Incheon
SONGDO, South Korea, July 20, 2020 /PRNewswire/ -- Samsung Biologics
(207940.KS) announced a plan to expand its Drug Product (DP) capability in line
with increasing market demand and to ensure flexible production capabilities
for new and existing clients.
2020-07-21 10:13
16037
New Early Breast Cancer Drug Now Approved in Malaysia
SINGAPORE, July 16, 2020 /PRNewswire/ -- A NEW breast cancer drug shown to significantly reduce the risk of cancer recurrence is now approved for use in Malaysia. The drug, NERLYNX (neratinib), is an oral medication taken by women with breast cancer who have had surgery, chemotherapy and prior tr...
2020-07-17 06:16
2320
I-Mab Announces Authorization of Stock Repurchase Program up to $20 Million
SHANGHAI and GAITHERSBURG, Md., July 15, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that its Board of Directors has authorized a stock repur...
2020-07-16 04:15
22208
Samsung Biologics and ImmuneOncia sign multi-product development and manufacturing agreement
SONGDO, South Korea, July 15, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and ImmuneOncia Therapeutics held a signing ceremony today for a contract to develop and manufacture five candidate molecules, expanding upon the two companies' existing CDO partnership first established in 2018. ...
2020-07-15 13:46
1898
Fosun Pharma Announces its Licensed COVID-19 Vaccine Product Receives Acceptance Notice of Clinical Trial Application by NMPA
SHANGHAI, July 14, 2020 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma", stock code: 600196.SH; 02196.HK) announces that its subsidiary Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. ("Fosun Pharmaceutical Industrial") has received the acceptance no...
2020-07-14 20:00
9951
Samsung Biologics signs additional development and manufacturing agreement with STCube
SONGDO, South Korea, July 11, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has further expanded its partnership with STCube through an additional development and manufacturing service agreement of STM418, an anti-PD1 immuno-oncology candidate. STM418 received much attention from the biopha...
2020-07-12 08:00
1832
Carromex Unveils Pharma Leads, a Groundbreaking Cloud-based Platform for Rapid Drug Analysis and Discovery
SYDNEY and MELBOURNE, Australia, July 9, 2020 /PRNewswire/ -- Carromex, a
mathematical research-based innovation company based inAustralia, unveiled a
new cloud-based pharmaceutical software platform called Pharma Leads
https://carromex.com/products/pharma-leads/
2020-07-10 11:31
1269
Asieris Received China NMPA's Approval to Start a Global Phase III Clinical Trial for APL-1702 to Treat Cervical Precancerous Lesions (HSIL)
SHANGHAI, July 8, 2020 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris), a China-based biotech company with global aspirations to discover, develop and commercialize innovative drugs for the treatment of genitourinary tumors and related diseases, announced today it has received Clinical Trial Ap...
2020-07-08 22:00
1383
ILIAS Biologics Granted Key Patent for Exosome-based Drug Delivery System in the United States
DAEJEON, South Korea, July 7, 2020 /PRNewswire/ -- ILIAS Biologics Inc. (the "Company" or "ILIAS"), a global leader in exosome-based therapeutics, announced today that the Company has been granted a key exosome engineering patent by the United States Patent and Trademark Office (USPTO). A patent...
2020-07-08 01:00
1390
Antengene Corporation Appoints Former BMS Senior Leader of Biostatistics Zhinuan YU as Corporate Vice President of Biometrics and Regulatory Enabling Functions
SHANGHAI and PHILADELPHIA, July 1, 2020 /PRNewswire/ --Antengene Corporation today announced its appointment of Zhinuan Yu, Ph.D., as Corporate Vice President (CVP) of Biometrics and Regulatory Enabling Functions. Zhinuan will be responsible for providing statistical leadership and strategic r...
2020-07-02 08:16
1585
Transcenta Announces First Patient Dosed in Phase I Clinical Trial of Claudin18.2 Targeting Monoclonal Antibody TST001 in the US
SUZHOU, China, July 1, 2020 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announced today that the first subject has been dosed successfull...
2020-07-01 23:00
1097
Coronavirus Breakthrough: New Study Highlights Senhwa Biosciences Silmitasertib as Potential Treatment for COVID-19
TAIPEI and SAN DIEGO, July 1, 2020 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on Next Generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that its drug Silmitasertib was again identified as o...
2020-07-01 21:00
2803
'Curing Cancer without Surgery'
* "Successful disappearance of tumors in subjects upon administering the pain-free anticancer drug, Polytaxel, without side effects such as weight loss." * Suppressed 99.8% of tumors despite a non-toxic dose…more effective than existing FDA-approved pancreatic cancer drugs. * Hopes for a Kore...
2020-06-30 15:10
1566
Alterity Therapeutics meeting with US FDA provides development pathway for ATH434
MELBOURNE, Australia and SAN FRANCISCO, June 29, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") is pleased to announce that it has received guidance from the US Food and Drug Administration (FDA) in relation to the development pathway for ATH434 ...
2020-06-30 11:14
6054
China Biologic Provides Additional Comments on the Xinjiang Deyuan and Shuanglin Transaction
BEIJING, June 29, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today declared that the Company disagrees with the notice delivered by Xinjiang Deyuan Bioeng...
2020-06-29 13:00
11959
Week's Top Stories
Most Reposted
Cornerstone Robotics Raises over US$70 million Funding to Forge Accessibility in Robotic Surgery
[Picked up by 323 media titles]
2025-01-13 09:05
URBAN REVIVO Celebrates Lunar New Year with Unique Collaboration with Artist Mercedes Bellido
[Picked up by 294 media titles]
2025-01-13 10:44
RuggON Launches VIKING II: Transforming Fleet Management with Unmatched Technology and Flexibility
[Picked up by 287 media titles]
2025-01-14 21:00
Gen Z Travelers Drive Buy Now, Plan Later Travel Bookings by Over 20%: Fliggy's 2024 Buy Now Plan Later Travel Insight
[Picked up by 286 media titles]
2025-01-10 16:04VANTAGE FOUNDATION SUPPORTS GRAB INDONESIA IN EMPOWERING WOMEN DRIVER-PARTNER
[Picked up by 280 media titles]
2025-01-09 18:26
Most Read
Hyundai Motor Group Partners with NVIDIA to Accelerate Development of AI Solutions for Future Mobility
2025-01-10 01:00
20406
AIMA Unveils Game-Changing 2025 eBike Lineup at CES: Better Performance, More Freedom
2025-01-09 02:34
6498
RingConn Takes Center Stage at CES 2025 with Innovative Wearables: Gen 2 and Gen 2 Air
2025-01-11 01:00
5688
Boqii Announces ADS Ratio Change
2025-01-11 05:30
4985
Sino Land Included in Dow Jones Sustainability World Index
2025-01-10 22:01
4966
